Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: A validated model using objective and readily available clinical parameters

Gut

Volumn 64, Issue 2, 2015, Pages 322-331

  Van Der Meer, Adriaan J ^a   Hansen, Bettina E ^a   Fattovich, Giovanna ^b   Feld, Jordan J ^c   Wedemeyer, Heiner ^d   Dufour, Jean François ^e   Lammert, Frank ^f   Duarte Rojo, Andres ^c   Manns, Michael P ^d   Ieluzzi, Donatella ^g   Zeuzem, Stefan ^h   Hofmann, W Peter ^h   De Knegt, Robert J ^a   Veldt, Bart J ^a   Janssen, Harry L A ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF VERONA   (Italy)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY OF VERONA   (Italy)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DISEASE COURSE; EPIDEMIOLOGY; HEPATITIS C, CHRONIC; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; VALIDATION STUDY; VIROLOGY;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NETHERLANDS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 84920969787     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305357     Document Type: Article

References (54)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
2. Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-45.
3. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21.
4. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
5. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-16, e1.
6. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
7. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7.
8. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-44.
9. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
11. Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
12. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010;32:2117-38.
13. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
14. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-8.
15. Van der Meer AJ, Veldt BJ, Feld JJ, et al. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat 2013. Published Online First: 10 October 2013 doi: 10.1111/jvh.12185
16. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
18. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403.
19. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
20. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-8.
21. Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007;5:932-7.
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
23. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
24. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-95.
25. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
26. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
27. Ambler G, Brady AR, Royston P. Simplifying a prognostic model: a simulation study based on clinical data. Stat Med 2002;21:3803-22.
28. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105.
29. Kremers WK. Technical Report Series No. 80, Concordance for Survival Time Data: Fixed and Time-dependent Covariates and Possible Ties in Predictor and Time. Rochester, Minnesota: Department of Health Science Research, Mayo Clinic, 2007.
30. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999;18:681-94.
31. Little R, Rubin D. Statistical Analysis With Missing Data. New York, NY: Wiley, 1987.
32. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011;18:e516-22.
33. Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. J Viral Hepat 2011;18:745-59.
34. Malinchoc M, Kamath PS, Gordon FD, et al . A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-71.
35. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
36. Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984;4:430-5.
37. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
38. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987;7:660-4.
39. Propst A, Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci 1995;40:1805-15.
40. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
41. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
42. Lv XH, Liu HB, Wang Y, et al. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1547-53.
43. Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903.
44. Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136-46.
45. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-41.
46. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31.
47. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-16.
48. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
49. Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-5.
50. Adams ST, Leveson SH. Clinical prediction rules. BMJ 2012;344:d8312.
51. Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003;23:45-53.
52. Verrill C, Markham H, Templeton A, et al. Alcohol-related cirrhosis - early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009;104:768-74.
53. Lazo M, Selvin E, Clark JM. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 2008;148:348-52.
54. Merchante N, Rivero-Juarez A, Tellez F, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012;56:228-38.